(Q35172428)

6 August 2017

1 reference

title

The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease (English)

1 reference

6 August 2017

0 references

0 references

1

Paul S Aisen

1 reference

PubMed ID

12849425

6 August 2017

language of work or name

1 reference

1 September 2002

1 reference

6 August 2017

1 reference

6 August 2017

1

1 reference

6 August 2017

279-284

1 reference

6 August 2017

5

1 reference

Alzheimer's disease: genes, proteins, and therapy

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Clearance of extracellular and cell-associated amyloid beta peptide through viral expression of neprilysin in primary neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

The search for disease-modifying treatment for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Inflammatory mechanisms in Alzheimer's disease: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Inflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

IL-1 and anti-inflammatory drugs modulate A beta cytotoxicity in PC12 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Interleukin-1, neuroinflammation, and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

The role of complement and activated microglia in the pathogenesis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Microglia and the immune pathology of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid-beta peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Risk of Alzheimer's disease and duration of NSAID use.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Anti-inflammatory drugs protect against Alzheimer disease at low doses.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Aspirin, anti-inflammatory drugs and risk of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: are they protective?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Clinical trial of indomethacin in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Dementia and subnormal levels of vitamin B12: effects of replacement therapy on dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

New insights into the mode of action of anti-inflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Induction of cyclooxygenase-2 mRNA and protein following transient focal ischemia in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Etanercept: a review of its use in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

1 reference

7 January 2021

The role of TNF and its receptors in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Interleukin-1beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900133-3

7 January 2021

10.1016/S1474-4422(02)00133-3

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12849425